Arginine depletion attenuates renal cystogenesis in tuberous sclerosis complex model

Cell Rep Med. 2023 Jun 20;4(6):101073. doi: 10.1016/j.xcrm.2023.101073. Epub 2023 Jun 7.

Abstract

Cystic kidney disease is a leading cause of morbidity in patients with tuberous sclerosis complex (TSC). We characterize the misregulated metabolic pathways using cell lines, a TSC mouse model, and human kidney sections. Our study reveals a substantial perturbation in the arginine biosynthesis pathway in TSC models with overexpression of argininosuccinate synthetase 1 (ASS1). The rise in ASS1 expression is dependent on the mechanistic target of rapamycin complex 1 (mTORC1) activity. Arginine depletion prevents mTORC1 hyperactivation and cell cycle progression and averts cystogenic signaling overexpression of c-Myc and P65. Accordingly, an arginine-depleted diet substantially reduces the TSC cystic load in mice, indicating the potential therapeutic effects of arginine deprivation for the treatment of TSC-associated kidney disease.

Keywords: ASS1; PTCs; TSC; arginine metabolism; argininosuccinate synthetase 1; cystogenesis; mTORC1; mechanistic target of rapamycin complex 1; proximal tubule cells; tuberous sclerosis complex.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arginine / metabolism
  • Humans
  • Kidney / metabolism
  • Mechanistic Target of Rapamycin Complex 1
  • Mice
  • Tuberous Sclerosis Complex 2 Protein / metabolism
  • Tuberous Sclerosis* / metabolism

Substances

  • Tuberous Sclerosis Complex 2 Protein
  • Arginine
  • Mechanistic Target of Rapamycin Complex 1